ReviewAutoimmunity reviews2023
Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature.
Review in Autoimmunity reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Dermatomyositis predominates among checkpoint inhibitor-associated inflammatory myositis phenotypes: a pharmacovigilance disproportionality analysis identifies a class-wide signal.Rheumatology international · 2026Article
- Autoantibodies as biomarkers of cancer risk in dermatomyositis.JID innovations : skin science from molecules to population health · 2026Review
- Dermatomyositis as a Paraneoplastic Syndrome of Metastatic Urothelial Carcinoma.Current oncology (Toronto, Ont.) · 2026Article
- Recurrent anti-TIF1γ-positive dermatomyositis coexisting with postoperative parotid lymphoepithelial carcinoma: a case report with pathogenesis analysis.Frontiers in immunology · 2026Article
- Prevention Works Best in Pairs: An Observational Study on Connubial Melanoma.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- New-onset dermatomyositis in a patient on nivolumab for metastatic melanoma.BMJ case reports · 2025Article
- Case Report: A rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer.Frontiers in oncology · 2025Article
- Risk, risk factors, and screening of malignancies in dermatomyositis: current status and future perspectives.Frontiers in oncology · 2025Review
- Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER.Frontiers in oncology · 2025Article
- Drug-induced dermatomyositis: a pharmacovigilance study of the FDA adverse event reporting system.Frontiers in pharmacology · 2025Article
- Immune Checkpoint Inhibitor Myopathy: The Double-Edged Sword of Cancer Immunotherapy.Neurology · 2024Review
- Recent Updates on the Pathogenesis of Inflammatory Myopathies.Current rheumatology reports · 2024Review
- Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy.Expert review of clinical immunology · 2024Review
- Immune Checkpoint Inhibitor-induced Myositis.Rheumatic diseases clinics of North America · 2024Review
- A comprehensive review of dermatomyositis treatments - from rediscovered classics to promising horizons.Expert review of clinical immunology · 2024Review
- Recent advances in understanding the immune microenvironment in ovarian cancer.Frontiers in immunology · 2024Review
- Deterioration in multifocal motor neuropathy upon treatment of immune-related adverse events of checkpoint inhibition.Immunotherapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 7 institutions in 3 countries.
Funding
Abstract
objectivesImmune checkpoint inhibitors (ICI) have revolutionized the treatment of several locally advanced and metastatic tumors. They enhance the effector function of the immune system, consequently leading to different immune-related adverse events. The aim of the present study was to describe three cases of dermatomyositis (DM) triggered by ICI diagnosed at our institution and to perform a review of the literature.
methodsWe performed a retrospective clinical, laboratory, and pathological evaluation of three cases of DM triggered by ICI belonging to a cohort of 187 DM patients from the Clinic Hospital Muscle Research Group of Barcelona from January 2009 to July 2022. Moreover, we undertook a narrative review of the literature from January 1990 to June 2022.
resultsCases from our institution were triggered by avelumab, an anti-PD-1 ligand (PD-L1), nivolumab, and pembrolizumab, both anti-programmed death-1 (PD-1). One of these patients had locally advanced melanoma, and two had urothelial carcinoma. The severity and response to treatment were heterogeneous among the different cases. All were positive at high titers for anti-TIF1γ autoantibodies; in one of them, serum before the onset of ICI was available, and anti-TIF1γ autoantibodies were already present. RNA expression of IFNB1, IFNG and genes stimulated by these cytokines were markedly elevated in these patients.
conclusionsIn conclusion, data from our patients and the narrative review suggest that early positivity to anti-TIF1γ unleashed by ICI may play a role in the development of full-blown DM, at least in some cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.